CLIMB BIO, INC. Debt Securities, Available-for-sale, Amortized Cost, Current
CLIMB BIO, INC. (CLYM) had Debt Securities, Available-for-sale, Amortized Cost, Current of $139.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $139.03M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $101.05M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $65.17M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $60.95M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2026-06-30 | $139.03M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $101.05M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $65.17M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $60.95M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $61.99M 10-Q · filed 2025-08-12 |
| 2024-12-31 | $63.65M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |